Checkpoint Therapeutics, Inc. financial data

Symbol
CKPT on Nasdaq
Location
95 Sawyer Road, Suite 110, Waltham, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 35.3 % +35.1%
Debt-to-equity -155 % -14.2%
Return On Equity 360 % +40.6%
Return On Assets -659 % +8.81%
Operating Margin -50.6K %

Shares

Label TTM Value / Value Unit Change %
Common Stock, Shares, Outstanding 45.1M shares +108%
Entity Public Float 33.1M USD -53.7%
Weighted Average Number of Shares Outstanding, Basic 43.2M shares +116%
Weighted Average Number of Shares Outstanding, Diluted 43.2M shares +116%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 41K USD +32.3%
Research and Development Expense 27.6M USD -44.2%
General and Administrative Expense 9.92M USD +6.76%
Operating Income (Loss) -37.5M USD +36%
Nonoperating Income (Expense) -8.95M USD -283%
Net Income (Loss) Attributable to Parent -46.5M USD +13.5%
Earnings Per Share, Basic -1.68 USD/shares +62.8%
Earnings Per Share, Diluted -1.68 USD/shares +62.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.7M USD +165%
Other Assets, Current 31K USD -35.4%
Assets, Current 5.18M USD +133%
Assets 5.18M USD +133%
Accounts Payable, Current 7.89M USD -0.83%
Employee-related Liabilities, Current 1.1M USD +8.47%
Liabilities, Current 17.8M USD -16.4%
Liabilities 17.8M USD -16.4%
Retained Earnings (Accumulated Deficit) -342M USD -15.7%
Stockholders' Equity Attributable to Parent -12.6M USD +33.9%
Liabilities and Equity 5.18M USD +133%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.47M USD +53.9%
Net Cash Provided by (Used in) Financing Activities 12.8M USD +87.8%
Common Stock, Shares Authorized 175M shares +119%
Common Stock, Shares, Issued 45.1M shares +108%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6.31M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.7M USD +165%
Deferred Tax Assets, Valuation Allowance 87.3M USD +34.8%
Deferred Tax Assets, Gross 87.3M USD +34.8%
Deferred Tax Assets, Operating Loss Carryforwards 45M USD +11.2%
Additional Paid in Capital 329M USD +19.2%